BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 10, 2003
View Archived Issues
New studies on atomoxetine presented at the APA meeting
Read More
TSU-68 active in patients with advanced solid tumors
Read More
CEP-701 reported to induce antitumoral effects in refractory AML
Read More
Good toxicity profile for CEP-7055 in patients with incurable solid tumors
Read More
Evidence of antitumor effects reported for ZD-6474 in refractory solid tumors
Read More
New PAF antagonists and their use as neuroprotectants described in recent patent
Read More
Pfizer claims novel protein kinase C inhibitors for use in pain, diabetic neuropathy, etc.
Read More
New antimicrobial carbapenems under study at Sumitomo
Read More
New factor Xa inhibitors, their preparation and use claimed by Kissei scientists
Read More
Maruha researchers identify new antagonists of Edg receptors
Read More
Novel EP2 receptor agonists with utility in glaucoma therapy discovered at Allergan
Read More
Schering-Plough researchers prepare and test new ORL-1 receptor agonists
Read More
New PPARgamma receptor modulators in Sankyo development pipeline
Read More
ImClone and BMS discuss Erbitux regulatory filing with FDA
Read More
GlaxoSmithKline advances development of GW-501516
Read More
Generex proposes acquisition of Antigen Express
Read More
Fujisawa and GSK sign U.S. copromotion agreement for Protopic
Read More
Ganymed and U. of Ghent come together for target validation
Read More
Roche's option to Vernalis A2A antagonist program in depression terminated
Read More
Dosing under way in phase II catheter occlusion trial of alfimeprase
Read More
Pivotal Actiza trial completes enrollment
Read More
Manufacturing of CoFactor underway
Read More
Enrollment completed in phase III alvimopan study in postoperative ileus
Read More
Nabi receives complete response for Nabi-HB
Read More
Medicure advances MC-4232 towards phase II/III
Read More
Grupo Vita signs marketing agreement for Eneas covering Turkey and Greece
Read More
Enrollment concluded in supportive phase III trial of Surfaxin for RDS
Read More
Phase III trial update on six-month Eligard product
Read More